In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
- TRADE NAMES: Afinitor (Novartis); Certican (Novartis); Zortress (Novartis)
- INDICATIONS: Prophylaxis of organ rejection in adults following kidney or liver transplant; advanced renal cell carcinoma; neuroendocrine tumors of pancreatic, gastrointestinal or lung origin; breast cancer in post-menopausal women with advanced hormone-receptor positive, HER2-negative type cancer; renal angiomyolipoma and tuberous sclerosis complex; subependymal giant cell astrocytoma associated with tuberous sclerosis
- CLASS: Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor), Immunosuppressant, mTOR inhibitor
- HALF-LIFE: ~30 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Aprepitant, Atazanavir, Atorvastatin, Benazepril, Captopril, Clarithromycin, Clozapine, Conivaptan, Cyclosporine, Darunavir, Delavirdine, Digoxin, Efavirenz, Enalapril, Erythromycin, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lapatinib, Lisinopril, Live vaccines, Nelfinavir, Oxcarbazepine, Phenytoin, Posaconazole, Quinapril, Ramipril, Ribociclib, Rifampin, Rifapentine, Ritonavir, Saquinavir, St John's Wort, Telithromycin, Venetoclax, Verapamil, Viloxazine, Voriconazole
- See adverse reactions attributed to class:
Antineoplastic / anticancer agent (see also Immune checkpoint inhibitor)
In immunosuppression therapy: MALIGNANCIES AND SERIOUS INFECTIONS, KIDNEY GRAFT THROMBOSIS; NEPHROTOXICITY
In heart transplantation: MORTALITY
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of everolimus in kidney transplantation in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/07/2024
